Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
@article{Hoos2016DevelopmentOI, title={Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations}, author={A. Hoos}, journal={Nature Reviews Drug Discovery}, year={2016}, volume={15}, pages={235-247} }
Since the regulatory approval of ipilimumab in 2011, the field of cancer immunotherapy has been experiencing a renaissance. This success is based on progress in both preclinical and clinical science, including the development of new methods of investigation. Immuno-oncology has become a sub-specialty within oncology owing to its unique science and its potential for substantial and long-term clinical benefit. Immunotherapy agents do not directly attack the tumour but instead mobilize the immune… CONTINUE READING
Figures, Tables, and Topics from this paper
Paper Mentions
284 Citations
Oncolytic viruses—immunotherapeutics on the rise
- Biology, Medicine
- Journal of Molecular Medicine
- 2016
- 40
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
- Medicine
- Oncoimmunology
- 2017
- 19
Recent advances in the clinical development of immune checkpoint blockade therapy
- Medicine
- Cellular Oncology
- 2019
- 27
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
- Medicine
- Seminars in liver disease
- 2018
- 29
Engineering immunity : enhancing T Cell vaccines and combination immunotherapies for the treatment of cancer
- Medicine
- 2017
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
- Biology, Medicine
- Oncoimmunology
- 2015
- 96
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies
- Medicine
- Annals of Surgical Oncology
- 2018
- 25
References
SHOWING 1-10 OF 178 REFERENCES
Big opportunities for small molecules in immuno-oncology
- Medicine
- Nature Reviews Drug Discovery
- 2015
- 211
- PDF
Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
- Medicine
- Seminars in oncology
- 2015
- 66
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
- Medicine
- Seminars in oncology
- 2010
- 200
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
- Medicine
- Current opinion in immunology
- 2015
- 239
Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.
- Medicine
- Seminars in oncology
- 2015
- 34
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
- Medicine
- The New England journal of medicine
- 2012
- 5,477
- PDF
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Medicine
- Nature
- 2014
- 1,708
- PDF